Press Release

Goodgut®, a line of first-in-class polyphenol-based prebiotic supplements garnering category interest and rapid retail growth, today announced a “first look” and sneak peek based on new scientific research regarding the role of its key ingredient, Preliva®, in preventing digestive distress and corresponding gut-initiated inflammation. The results of a recently conclusive laboratory test rat study conducted in Palo Alto, California in partnership with PMI Preclinical CRO, revealed that rats fed a standard high fat, high sugar Western Diet supplemented with Preliva® experienced markedly reduced lipopolysaccharide (LPS) accumulation, indicating a major reduction in systemic inflammation.

Goodgut® is the flagship product line from Greenteaspoon, Inc., a Silicon Valley-based leading-edge digestive health company established in 2012.  Marketed under the product names Rescue, Balance and Boost, Goodgut® brand products have been proven to be effective at the highest standard of clinical science, having undergone a double blind, peer-reviewed randomized clinical study. Encouraged by the initial findings of the clinical study, the scientists behind Goodgut® completed a 42 day rat study in July 2017 to explore the potential for Preliva® to reduce LPS levels, which stem from the negative impact of high fat, high sugar food consumption on the “microbiome.”

Scientists across the U.S. have long known that LPS is a potent initiator of inflammation in humans and in animal test subjects. Because LPS, which is also referred to as an “endo-toxin,” is a highly pro-inflammatory component of the cell wall of bacteria in the digestive tract, it is associated not only with gut illness, but it is also a precursor of many of the most important chronic human and animal disease processes. These include diabetes, obesity, cardiovascular disease and liver disease, Alzheimer’s and Parkinson’s diseases and dementia.

Because LPS cannot be accurately measured directly in the blood in order to determine systemic levels of inflammation, scientists instead measure LBP (lipopolysaccharide binding protein). In the 2017 Preliva® rat study, LBP levels in the group of rats whose Western Diets were supplemented with Preliva® were significantly lower than the group of rats fed a Western Diet without Preliva® supplementation, and nearly identical to LBP levels in the group of rats who received a normal, low fat, low sugar diet.

During the same Preliva® study, FABP-2 (Fatty Acid Binding Protein-2, which is made by the cells lining the digestive tract) levels were also measured. The amount of FABP-2 found in the blood is used to determine the extent the digestive tract damage. Higher levels of FABP-2 indicate more extensive damage.

Breakthrough results from this study revealed that Preliva® prevented damage to the digestive tract caused by a Western Diet, as determined by measuring FABP-2.  Preliva® also prevented lipopolysaccharide (LPS) and its inflammation causing properties from leaking across the lining of the digestive tract of the rats participating in the study. These findings constitute a significant early and optimistic indicator of the potential for Goodgut’s safe and natural Preliva® ingredient in not only alleviating the effects of unwanted digestive ailments such as occasional diarrhea, upset stomach, gas and bloating, but also in helping to potentially combat the potent inflammatory process that accompanies consumption of the pervasive Western diet.

“We could not be more excited about the early promise for Preliva® that our recent preliminary rat testing studies have yielded,” said Rob Wotring, founder and CEO of Greenteaspoon, Inc., developer of Preliva® and Goodgut®. “This breakthrough prebiotic nourishes beneficial digestive bacteria, helping to restore balance to digestive and immune health. But most importantly, while Preliva® works specifically to fortify the protective layer that lines the digestive tract and help stop “leaky gut,” it may also have a significant, measurable impact in curtailing the inflammatory process. This could have a potentially game-changing impact on not only the probiotics/prebiotics supplement industry, but also at a fundamental level on our continued quest toward understanding and finding solutions to managing runaway human whole body inflammation on a systemic level.”

For additional information on Goodgut® and Preliva®, and the recent Preliva® rat control study preliminary findings, please visitwww.goodgut.com.

The complete results of this comprehensive study, along with clinical analysis, will be released to the peer review journal community in the fall of this year.

About Goodgut®

Goodgut®, a line of first-in-class polyphenol-based prebiotic supplements, is a safe and natural solution that alleviates occasional diarrhea, upset stomach, gas and bloating. The breakthrough prebiotic, proven to be effective at the highest standard of clinical science and having undergone a double-blind, peer-reviewed randomized clinical study, nourishes beneficial digestive bacteria and helps to restore balance to digestive and immune health. Goodgut® is the flagship product line from Greenteaspoon, Inc., a Silicon Valley-based digestive health company established in 2011. Goodgut®—helping to keep your body in balance...no matter what life throws your way.